Who is sponsoring NCT02238301?

NCT02238301 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT02238301?

Interventions in NCT02238301: Bold sequence patients test, Bold + ASL sequence.

What condition does NCT02238301 study?

NCT02238301 studies Intrauterine Growth Restriction.

Is NCT02238301 still recruiting?

NCT02238301 is currently completed. Last updated 8 September 2025.

Last reviewed 2025-09-08 · How we verify

NCT02238301: BOLD-FP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Fetoplacental Oxygenation With Functional MRI in Pregnant Women

Completed NA Last updated 8 September 2025

What this trial tests

NA trial testing Bold sequence patients test in Intrauterine Growth Restriction in 101 participants. Completed in 26 September 2019.

Timeline

18 February 2015

Primary endpoint
26 September 2019

26 September 2019

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	101
Start date	18 February 2015
Primary completion	26 September 2019
Estimated completion	26 September 2019
Sites	1 location across France

Drugs / interventions tested

Bold sequence patients test
Bold + ASL sequence

Conditions studied

Intrauterine Growth Restriction — all drugs for Intrauterine Growth Restriction →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, female only, with Intrauterine Growth Restriction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the use of functional MRI in pregnant women as a non-invasive diagnostic tool to detect placental insufficiency and differentiate healthy fetuses from the intra-uterine growth restricted ones. Functional MRI in pregnant women can detect a variation of the MRI signal (called BOLD effect) from the placenta and the fetus when the mother is breathing pure oxygen. This study aims hence to demonstrate the difference in the BOLD effect between normal feto-placental units and growth restricted ones.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Placental T2* and BOLD effect in response to hyperoxia in normal and growth-restricted pregnancies: multicenter cohort study.
Jacquier M, Chalouhi G, Marquant F, Bussieres L, et al · · 2024 · cited 1× · PMID 37743665 · DOI 10.1002/uog.27496

Verify or expand the search:

Other recruiting trials for Intrauterine Growth Restriction

Currently open trials in the same condition.

NCT06534307 — Long-term Follow-up of Children Born in the PETN Studies · recruiting
NCT06115122 — PEPPI Study: Identification of Women at Risk for Placental Dysfunction · recruiting
NCT06074601 — MIRACLE of LIFE Study · active not recruiting
NCT04766866 — sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term. · NA · recruiting
NCT03398629 — Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies · recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02238301 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 8 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02238301.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing